Abivax’s ABX464 enticing in theory for Covid-19 but mechanism, trial design issues belie potential for success
Pfizer and BioNTech have reported positive, preliminary results from the ongoing Phase I/II clinical trial of mRNA-based Covid-19 vaccine candidate, BNT162b1, in the US.
UK-based contract development and manufacturing company Almac Group’s unit Almac Clinical Services has announced that it had digitised its on-site auditing process and unveiled a virtual auditing solution for global clients.
Mexico is reportedly planning to carry out late stage trials for coronavirus (Covid-19) vaccines being developed by companies in the US and China.
Biopharmaceutical company Romark Laboratories has commenced Phase III trial of its new investigational drug candidate NT-300 (nitazoxanide).
US-based Arcturus Therapeutics has dosed the first group of participants in the Phase I/II clinical study of its Covid-19 vaccine candidate.
Vaccination is being considered as the only way the coronavirus pandemic can be controlled, although a highly effective vaccine is not expected to be available in less than a year.
Pharming Group has started enrolment in a clinical trial of Ruconest, a recombinant human C1 inhibitor, for the treatment of hospitalised Covid-19 patients.
Seres Therapeutics has reported positive top-line data from the Phase III ECOSPOR III clinical trial of SER-109 to treat recurrent C difficile infection (CDI).
Roche has reported mixed top-line data from the Phase III clinical study programme of etrolizumab in patients with moderately to severely active ulcerative colitis.